Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Article

A Simple Parallel Analytical Method of Prenatal Screening

Li D.a · Yang H.a · Zhang W-H.a · Pan H.a · Wen D.-Q.a · Han F.-C.a · Guo H.-F.a · Wang X.-M.b · Yan X.-J.a

Author affiliations

aInstitute of Genetic Diagnosis, School of Pharmacy, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi’an, and bShenzhen Sino Co., Ltd, Shenzhen, China

Related Articles for ""

Gynecol Obstet Invest 2006;62:220–225

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: March 30, 2005
Accepted: May 03, 2006
Published online: November 15, 2006
Issue release date: November 2006

Number of Print Pages: 6
Number of Figures: 4
Number of Tables: 2

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Abstract

Protein microarray has progressed rapidly in the past few years, but it is still hard to popularize it in many developing countries or small hospitals owing to the technical expertise required in practice. We developed a cheap and easy-to-use protein microarray based on dot immunogold filtration assay for parallel analysis of ToRCH-related antibodies including Toxoplasma gondii, rubella virus, cytomegalovirus and herpes simplex virus type 1 and 2 in sera of pregnant women. It does not require any expensive instruments and the assay results can be clearly recognized by the naked eye. We analyzed 186 random sera of outpatients at the gynecological department with our microarray and commercial ELISA kit, and the results showed there was no significant difference between the two detection methods. Validated by clinical application, the microarray is easy to use and has a unique advantage in cost and time. It is more suitable for mass prenatal screening or epidemiological screening than the ELISA format.

© 2006 S. Karger AG, Basel


References

  1. Boutell JM, Hart DJ, Godber BL, Kozlowski RZ, Blackburn JM: Functional protein microarrays for parallel characterisation of p53 mutants. Proteomics 2004;4:1950–1958.
  2. Lue RY, Chen GY, Zhu Q, Lesaicherre ML, Yao SQ: Site-specific immobilization of biotinylated proteins for protein microarray analysis. Methods Mol Biol 2004;264:85–100.
  3. Lu DD, Chen SH, Zhang SM, Zhang ML, Zhang W, Bo XC, Wang SQ: Screening of specific antigens for SARS clinical diagnosis using a protein microarray. Analyst 2005;130:474–482.
  4. Kader HA, Tchernev VT, Satyaraj E, Lejnine S, Kotler G, Kingsmore SF, Patel DD: Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-β1, and IL-12p40 levels in Crohn’s disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 2005;100:414–423.
  5. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005;65:767–779.
  6. Reddy KS, Perrotta PL: Proteomics in transfusion medicine. Transfusion 2004;44:601–604.
  7. Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP: Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005;23:36–46.
  8. Wulfkuhle J, Espina V, Liotta L, Petricoin E: Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 2004;40:2623–2632.
  9. Chen Y, Qian X, Tang Z, Banta HD, Hu F, Cao J, Huang J, Wang Q, Lv J, Ying X, Chen J: Situation analysis of prenatal diagnosis technology utilization in China: current situation, main issues, and policy implications. Int J Technol Assess Health Care 2004;20:524–530.
  10. Best JM: Laboratory diagnosis of intrauterine and perinatal virus infections. Clin Diagn Virol 1996;5:121–129.
  11. Gerber S, Hohlfeld P: Screening for infectious diseases. Childs Nerv Syst 2003;19:429–432.
  12. Stegmann BJ, Carey JC: ToRCH infections. Toxoplasmosis, other (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus (CMV), and herpes infections. Curr Womens Health Rep 2002;2:253–258.
    External Resources
  13. Liu YJ, Liu Y, Qu YH, Zheng Y, Liu YH, Zhang YL, Chen J: Application of dot-immunogold filtration assay in detection of IgG in sera of trichinellosis patients. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003;21:342–344.
    External Resources
  14. Chen X, Yang XY, Wang ND, Ding C, Yang YJ, You ZJ, Su Q, Chen JH: Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction. Scand J Clin Lab Invest 2003;63:497–503.
  15. Shao ZJ, Xu DZ, Yan YP, Li JH, Zhang JX, Zhang ZY, Pan BR: Detection of anti-HAV antibody with dot immunogold filtration assay. World J Gastroenterol 2003;9:1508–1511.
  16. Han FC, Hou Y, Yan XJ, Xiao LY, Guo YH: Dot immunogold filtration assay for rapid detection of anti-HAV IgM in Chinese. World J Gastroenterol 2000;6:400–401.
  17. Xiao LY, Yan XJ, Mi MR, Han FC, Hou Y: Preliminary study of a dot immunogold filtration assay for rapid detection of anti-HCV IgG. World J Gastroenterol 1999;5:349–350.
  18. Bacarese-Hamilton T, Mezzasoma L, Ardizzoni A, Bistoni F, Crisanti A: Serodiagnosis of infectious diseases with antigen microarrays. J Appl Microbiol 2004;96:10–17.
  19. Coleman MA, Lao VH, Segelke BW, Beernink PT: High-throughput, fluorescence-based screening for soluble protein expression. J Proteome Res 2004;3:1024–1032.
  20. Kukar T, Eckenrode S, Gu Y, Lian W, Megginson M, She JX, Wu D: Protein microarrays to detect protein-protein interactions using red and green fluorescent proteins. Anal Biochem 2002;306:50–54.
  21. Lyng H, Badiee A, Svendsrud DH, Hovig E, Myklebost O, Stokke T: Profound influence of microarray scanner characteristics on gene expression ratios: analysis and procedure for correction. BMC Genomics 2004;5:10.
  22. Dodd LE, Korn EL, McShane LM, Chandramouli GV, Chuang EY: Correcting log ratios for signal saturation in cDNA microarrays. Bioinformatics 2004;20:2685–2693.
  23. Saravanan P, Kumar S, Kataria JM: Use of multiple antigenic peptides related to antigenic determinants of infectious bursal disease virus (IBDV) for detection of anti-IBDV-specific antibody in ELISA – quantitative comparison with native antigen for their use in serodiagnosis. J Immunol Methods 2004;293:61–70.
  24. Ndongmo CB, Switzer WM, Pau CP, Zeh C, Schaefer A, Pieniazek D, Folks TM, Kalish ML: New multiple antigenic peptide-based enzyme immunoassay for detection of simian immunodeficiency virus infection in nonhuman primates and humans. J Clin Microbiol 2004;42:5161–5169.
  25. Saravanan P, Satishkumar, Kataria JM, Rasool TJ: Detection of Infectious bursal disease virus by ELISA using an antipeptide antibody raised against VP3 region. Acta Virol 2004;48:39–45.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: March 30, 2005
Accepted: May 03, 2006
Published online: November 15, 2006
Issue release date: November 2006

Number of Print Pages: 6
Number of Figures: 4
Number of Tables: 2

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.